Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12589789 | 1.00 | CYP1A2 (0.46) | CYP1A2POLBCYP3A4CYP2C19NR1H2 | |
| SCHEMBL6842749 | 1.00 | CYP1A2 (0.46) | CYP1A2POLBCYP3A4CYP2C19NR1H2 | |
| SCHEMBL6847628 | 0.90 | P2RX3 (0.44) | CYP1A2POLBCYP3A4CYP2C19NR1H2 | |
| SCHEMBL14175326 | 0.90 | MMP2 (0.44) | CYP1A2POLBCYP3A4CYP2C19NR1H2 | |
| SCHEMBL5063285 | 0.90 | MMP2 (0.44) | CYP1A2POLBCYP3A4CYP2C19NR1H2 | |
| SCHEMBL6847624 | 0.90 | P2RX3 (0.44) | CYP1A2POLBCYP3A4CYP2C19NR1H2 | |
| SCHEMBL6847598 | 0.89 | NR1H2 (0.44) | CYP1A2POLBCYP3A4CYP2C19NR1H2 | |
| SCHEMBL700092 | 0.89 | NR1H2 (0.44) | CYP1A2POLBCYP3A4CYP2C19NR1H2 | |
| SCHEMBL6847765 | 0.89 | NR1H2 (0.44) | CYP1A2POLBCYP3A4CYP2C19NR1H2 | |
| SCHEMBL6848112 | 0.88 | CYP1A2 (0.45) | CYP1A2POLBCYP3A4CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968733-B2 | Pyrrolidine analogue for preventing neurogenic pain and method for production thereof | GIFU UNIVERSITY (JP) | 2011-06-28 | — | — | US | disclosed |
| US-7968733-B2 | Pyrrolidine analogue for preventing neurogenic pain and method for production thereof | GIFU UNIVERSITY (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20090306407-A1 | Pyrrolidine analogue for preventing neurogenic pain and method for production thereof | GIFU UNIVERSITY (JP) | 2009-12-10 | — | — | US | disclosed |
| US-20090306407-A1 | Pyrrolidine analogue for preventing neurogenic pain and method for production thereof | GIFU UNIVERSITY (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2058301-A1 | PYRROLIDINE ANALOGUE FOR PREVENTING NEUROGENIC PAIN AND METHOD FOR PRODUCTION THEREOF | Gifu University (JP) | 2009-05-13 | — | — | EP | disclosed |
| US-6770741-B1 | USEFUL IN TREATING CONDITIONS AND DISEASES OF A MAMMAL AND HUMAN IN WHICH AN EXCESS OF BRADYKININ OR RELATED KININS ARE PRODUCED OR INJECTED SUCH AS BY INSECT BITES | SCIOS INC. | 2004-08-03 | — | — | US | disclosed |
| EP-0618810-B1 | BRADYKININ ANTAGONIST PEPTIDES | SCIOS NOVA INC (US) | 2001-07-04 | — | — | EP | disclosed |
| US-5385889-A | Substitution of L-proline at the 7-position of the peptide hormone with a D-configuration hydroxyproline ether or thioether converts agonist into antagonist | SCIOS NOVA INC. (US) | 1995-01-31 | — | — | US | disclosed |
| EP-0618810-A4 | BRADYKININ ANTAGONIST PEPTIDES. | SCIOS NOVA INC (US) | 1994-12-07 | — | — | EP | disclosed |
| EP-0618810-A1 | BRADYKININ ANTAGONIST PEPTIDES | SCIOS NOVA INC. (US) | 1994-10-12 | — | — | EP | disclosed |
| WO-1992018156-A1 | BRADYKININ ANTAGONIST PEPTIDES | NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306407-A1 | Pyrrolidine analogue for preventing neurogenic pain and method for production thereof | HNMT, OPRK1, OPRL1 | CYP1A2 3856/4885POLB 1073/4885CYP3A4 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.